Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Herman

Showing results (271-280 of 316) with videos related to

Pageof 32
Sort By:
Journal of Gastrointestinal Oncology|April 2, 2015
Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreasAaron T Wild, Avani S Dholakia, Katherine Y Fan, et al.
Practical Radiation Oncology|August 25, 2016
Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancerAvani D Rao, Elizabeth A Sugar, Daniel T Chang, et al.
Oncology (Williston Park, N.Y.)|August 19, 2015
ACR Appropriateness Criteria® Resectable Stomach CancerParima Daroui, Salma K Jabbour, Joseph M Herman, et al.
Journal of the American College of Radiology : JACR|May 6, 2017
ACR Appropriateness Criteria<sup>®</sup> Pretreatment Staging of Colorectal Cancer, Kathryn J Fowler, Harmeet Kaur, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2013
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinomaJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 20, 2021
Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life CareMatthew S Ning, Prajnan Das, David I Rosenthal, et al.
Annals of Surgical Oncology|August 27, 2021
Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic CancerGeorgios Gemenetzis, Alex B Blair, Minako Nagai, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2024
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal AdenocarcinomaColin S Hill, Rose Parkinson, Elizabeth M Jaffee, et al.
Annals of Surgical Oncology|January 8, 2015
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution ExperienceShalini Moningi, Avani S Dholakia, Siva P Raman, et al.
Journal of Gastrointestinal Oncology|December 3, 2013
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutionsAaron T Wild, Susan M Hiniker, Daniel T Chang, et al.
Pageof 32

Showing results (271-280 of 316) with videos related to

Sort By:
Pageof 32
Journal of Gastrointestinal Oncology|April 2, 2015
Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreasAaron T Wild, Avani S Dholakia, Katherine Y Fan, et al.
Practical Radiation Oncology|August 25, 2016
Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancerAvani D Rao, Elizabeth A Sugar, Daniel T Chang, et al.
Oncology (Williston Park, N.Y.)|August 19, 2015
ACR Appropriateness Criteria® Resectable Stomach CancerParima Daroui, Salma K Jabbour, Joseph M Herman, et al.
Journal of the American College of Radiology : JACR|May 6, 2017
ACR Appropriateness Criteria<sup>®</sup> Pretreatment Staging of Colorectal Cancer, Kathryn J Fowler, Harmeet Kaur, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2013
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinomaJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 20, 2021
Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life CareMatthew S Ning, Prajnan Das, David I Rosenthal, et al.
Annals of Surgical Oncology|August 27, 2021
Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic CancerGeorgios Gemenetzis, Alex B Blair, Minako Nagai, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2024
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal AdenocarcinomaColin S Hill, Rose Parkinson, Elizabeth M Jaffee, et al.
Annals of Surgical Oncology|January 8, 2015
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution ExperienceShalini Moningi, Avani S Dholakia, Siva P Raman, et al.
Journal of Gastrointestinal Oncology|December 3, 2013
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutionsAaron T Wild, Susan M Hiniker, Daniel T Chang, et al.
Pageof 32